Gensight Biologics (XPAR:SIGHT) EV-to-EBIT : -2.50 (As of May. 16, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gensight Biologics's Enterprise Value is €57.72 Mil. Gensight Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-23.07 Mil. Therefore, Gensight Biologics's EV-to-EBIT for today is -2.50.

The historical rank and industry rank for Gensight Biologics's EV-to-EBIT or its related term are showing as below:

XPAR:SIGHT' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.06 Med: -3.51 Max: -0.84
Current: -2.5

During the past 12 years, the highest EV-to-EBIT of Gensight Biologics was -0.84. The lowest was -9.06. And the median was -3.51.

XPAR:SIGHT's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs XPAR:SIGHT: -2.50

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Gensight Biologics's Enterprise Value for the quarter that ended in Dec. 2023 was €46.18 Mil. Gensight Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-23.07 Mil. Gensight Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -49.96%.

Gensight Biologics EV-to-EBIT Historical Data

The historical data trend for Gensight Biologics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics EV-to-EBIT Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-2.28

-8.30

-8.51

-6.30

-2.00

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-8.51	-	-6.30	-	-2.00

Competitive Comparison of Gensight Biologics's EV-to-EBIT

For the Biotechnology subindustry, Gensight Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's EV-to-EBIT falls into.

Gensight Biologics EV-to-EBIT Calculation

Gensight Biologics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	57.717	/	-23.069
	=	-2.50

Gensight Biologics's current Enterprise Value is €57.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-23.07 Mil.

Gensight Biologics (XPAR:SIGHT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Gensight Biologics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-23.069	/	46.178222
	=	-49.96 %

Gensight Biologics's Enterprise Value for the quarter that ended in Dec. 2023 was €46.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-23.07 Mil.

Gensight Biologics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines